Association Between Cathepsin S, Cystatin C and High Sensitivity C-Reactive Protein (hsCRP) with Oxidized LDL (Ox-LDL) in Men with Central Obesity

Emmy F Harefa, Ilhamjaya Patellongi, Marita Kaniawati

Abstract


BACKGROUND: Inflammation is a central feature of the atherosclerotic process particularly in obesity. hsCRP, a marker of inflammation, may be directly involved in all phases of atheroslerosis by complement activation, apoptosis, vascular cell activation, monocyte recruitment, lipid accumulation and thrombosis. Inflammation has a causal relationship with cysteine proteases including cathepsin S. Therefore, cathepsin S is considered as a molecular link between obesity and atherosclerosis. An imbalance between elastolytic cysteine proteases, cathepsin S and its inhibitor, cystatin C, is involved in the pathogenesis of atherosclerosis. Some studies have shown that increased circulating levels of cathepsin S, hsCRP and cystatin C in inflammatory conditions contribute to atherosclerosis. This study was conducted to investigate the associations between ox-LDL and cathepsin S, and cystatin C and hsCRP in men with central obesity.

METHODS: This was a cross-sectional study involving 71 male subjects with central obesity (waist circumference ≥90 cm), with no renal dysfunction, aged 30-60 years.

RESULTS: Cathepsin S did not have a significant correlation with ox-LDL (r=0.158, p=0.096). ox-LDL had positive correlation with cystatin C (r=0.156; p=0.029) and hsCRP (r=0.204; p=0.045), and cathepsin S/cystatin C ratios (r=0.360; p=0.024) at level >91 U/L (median ox-LDL).

CONCLUSIONS: There were associations between ox-LDL and cystatin C, hsCRP and cathepsin S/cystatin C ratios in men with central obesity.

KEYWORDS: obesity, inflammation, atherosclerosis, hsCRP, cystatin C, cathepsin S, ox-LDL


Full Text:

PDF

References


Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 550-62, CrossRef.

Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Hindawi Publishing Corporation. 2010; 20: 1-17, CrossRef.

Jobs E, lngelsson E, Riserus U, Nerpin E, Jons M, Sundstromm K, et al. Association between serum cathepsin S and modality in older adults. JAMA. 2011; 306: 1113-21, CrossRef.

Fei-fei, G LU, Shu-zheng, Yun-dai C, Yu-jie Z, Xian-tao S, et al. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J. 2009; 122: 2820-26, PMID.

Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999; 104: 1191-7, CrossRef.

Kim EH, Yu JH, Lee SA, Kim EY, Kim WG, Lee SH, et al. Lack of association between serum cystatin C levels and coronary artery disease in diabetic patients. Korean Diabetes J. 2010; 34: 209-10, CrossRef.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-7, CrossRef.

Korolenko TA, Cherkanova MS, Gashenko EA, Johnston TP, Brave IY. Cystatin C, aterosclerosis and lipid lowering therapy by statins. In: Cohen JB, Ryseck LP, editors. Cystatin: protease inhibitor, biomarkers, and immunomodulators. USA: Nova Science Publisher; 2010. p.187-203, NLMID.

Zhang H, Cui J, Zhang C. Emerging role of adipokines: as mediators in atherosclerosis. World J Cardiol. 2010; 26: 370-6, CrossRef.

Bengtsson E, Hakansson K, Grubb A, Branén L. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E - deficient mice. Arterioscler Thromb Vase Biol. 2005; 25: 2151-6, CrossRef.

Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 1359-66, CrossRef.

Arnlév J. Cathepsin S as a biomarker: where are we now and what are the future challenges? Biomarkers Med. 2012; 6: 9-11, CrossRef.

George SJ, Johnson J. Atherosclerosis: molecular and cellular mechanism. Weinheim: Wiley Blackwell Publisher; 2010, link.

Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, et al. Cystatin C and inflammatory markers in the ambulatory elderly. Am J Med. 2005; 118: 1416.e25-31, CrossRef.

Taglieri N, Koenig W, Kaski CJ. Cystatin C and cardiovascular risk. Clin Chem. 2009; 55: 1932-43, CrossRef.

Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A, et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005; 96: 368-75, CrossRef.

Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis. 2011; 216: 440-5, CrossRef.

Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med. 2011; 49: 1397-404, CrossRef.

Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Reports. 2006; 8: 55-61, CrossRef.

McCormick SPA. Lipoprotein (a): Biology and clinical importance. Clin Biochem Rev. 2004; 25: 69-80, PMID.

Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med. 2012; 3: 428-35, PMID.

Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res. 2006; 71: 30-9, CrossRef.

Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007; 21: 3029-41, CrossRef.

Taleb S, Cancello R, Poitou C, Rouault C, Sellam P, Levy P, et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab. 2006; 91: 1042-7, CrossRef.

Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109: II2-10, CrossRef.

Paffen E, Moniek PM. C-reactive protein in atherosclerosis: A causal factor? Cardiovascular Research. 2006; 71: 30-9, CrossRef.

Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 2003; 144: 2195-200, CrossRef.




DOI: https://doi.org/10.18585/inabj.v4i1.162

Copyright (c) 2012 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                

 

 

The Prodia Education and Research Institute